Evaluation of an automated cell processing device to reduce the dimethyl sulfoxide from hematopoietic grafts after thawing

Abstract

Washing out DMSO in thawed HPC-A by use of this approach is safe and efficient in terms of recovery and viability of nucleated and progenitor cells. Additionally, the removal degree of DMSO is very high and therefore might ameliorate the transfusion-related side effects.

The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product

“…Several studies have reported a lower incidence of adverse events when DMSO is depleted from the autograft prior to the infusion. [8][9][10] However, the laboratory procedure is time consuming and side effects continue to occur despite removal of DMSO. 10 In a large series of 460 patients in which DMSO was removed prior to infusion, adverse events were still reported despite an adequate histamine blockade, suggesting the presence of granulocyte contamination as the cause of these adverse reactions.…”

Cryopreservation of Canine Platelets

“…Reported adverse effects of administration of DMSO cryopreserved cells (most commonly hematopoietic progenitor cells) to human patients range from mild, such as nausea, vomiting, flushing, fever, and abdominal pain, to severe complications, including dyspnea, hypo-or hypertension, and abnormalities of the renal, cardiovascular, and neurologic systems. 26 Given that administration of 6% DMSO cryopreserved platelets was well tolerated by 10 of 11 dogs in this study receiving 10 mL/kg of PC, washing of platelets to remove DMSO does not appear necessary when moderate volumes of PC are transfused. However, administration of a large volume of 6% DMSO cryopreserved platelets to critically ill dogs may warrant additional monitoring for potential adverse effects of DMSO.…”

Autologous Stem Cell Transplantation in the Treatment of Amyloidosis – Can Manipulation of the Autograft Reduce Treatment-Related Toxicity?

“…Some of the studies where DMSO depletion was utilized, included a large group of patients without bone marrow disease and may not be representative for the present use of autologous peripheral blood stem cell transplantation for hematological malignancies with diffuse infiltration of malignant cells throughout the bone marrow (Calmels et al, 2003;Rodriguez et al, 2005). These preclinical studies investigated grafts of highly selected patients who relapsed or died before autotransplantation could be done (Calmels et al, 2003;Rodriguez et al, 2005). Furthermore, Foïs et al cryopreserved autografts with voluven + DMSO 10% and not DMSO alone, and they did not include detailed analyses of engraftment and transfusion.…”

“…Lemarie and colleagues used comprehensive automated washing to reach more than 20-fold reduction of DMSO-levels, whereas Syme and coworkers investigated patients with solid tumors and used a relatively extensive manual DMSO depletion (Lemarie et al, 2005;Syme et al, 2004). In the preclinical studies mentioned above (Calmels et al, 2003;Rodriguez et al, 2005), the researhers used a device; CytoMate TM , to perform the washing procedure with phosphate buffered saline (PBS) plus 5% Dextran-40, 5% ACD-A and 1-5% human serum albumin (HSA). While Calmels et al achieved more than 96% elimination of DMSO and a mean recovery of viable total cells, CD34+ cells and lymphocyte subsets above 60%, Rodriguez et al reported 98% DMSO elimination and 103% CD34+ cell recovery.…”